News Spark divides opinion with $850,000 gene therapy Spark offers efficacy-based rebates and deferred payments to mitigate costs
News Shire tipped as next big pharma takeover target After trial failure, shares rallied on takeover rumours
News Shire's Hunter Syndrome cognitive impairment drug fails Trial missed primary and secondary endpoints
News First ever 'off the shelf' stem cell therapy nears European ... Alofisel recommended for complex perianal fistulas in Crohn's disease
News Ultragenyx to slash costs after Angelman trial failure Ultragenyx's therapy for the rare genetic disorder Angelman syndrome, apazunersen, has flunked a late-stage trial, crashing its share price.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
